R&D channel feed

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Yesterday

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Yesterday
Pharma

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

2 days ago

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

2 days ago

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

2 days ago
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

2 days ago
Pharma

BioN­Tech in­vests £1B in grow­ing UK foot­print un­der ex­pand­ed pact with gov­ern­ment

3 days ago
Deals

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

3 days ago

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

4 days ago
Deals

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

4 days ago

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

4 days ago
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

4 days ago
Cell/Gene Tx

Tour­ma­line Bio's heart drug cuts in­flam­ma­tion as it seeks to com­pete with No­vo, CSL's as­sets 

4 days ago

Boehringer In­gel­heim’s late-stage da­ta for lung dis­ease can­di­date un­der­whelm some an­a­lysts

5 days ago

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

5 days ago
People
Cell/Gene Tx

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

5 days ago
Pharma
Cell/Gene Tx

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

5 days ago
Cell/Gene Tx

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

6 days ago
Startups

Sarep­ta seeks to ex­pand Duchenne gene ther­a­py Ele­v­idys use to tod­dlers

Last week
FDA+

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

Last week
Cell/Gene Tx

In three pa­tients, Rock­et’s sec­ond heart gene ther­a­py shows promise

Last week
Cell/Gene Tx

RFK Jr. adopts new chikun­gun­ya vac­cine guid­ance; oth­er rec­om­men­da­tions re­main un­der re­view

Last week
Pharma
FDA+

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Last week
Cell/Gene Tx
In Focus

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

Last week
Cell/Gene Tx
1234 Next page Last page
A service from the Financial Times